PRIMARY STUDY
UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease
Key Findings: This analysis finds that cannabis-based medicinal products (CBMPs) provided symptom improvement in patients with inflammatory bowel disease (IBD) and generally improved health-related quality of life.
Type of Study: Meta-analysis
Study Sample Size: 116
Study Result: Positive
Research Location(s): United Kingdom
Year of Pub: 2024
Cannabinoids Studied: Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
DOSING DETAILS 
Study Dosing Objective: Effective Dose,
Established Protocol: Effective dose
Cannabinoid Ratio: (THC : CBD) 195 : 35 
Dosing Regimen: median doses of CBD and THC of 35 and 195 mg/day dried flower only had median doses of CBD and THC of 15 and 210 mg/day prescribed oils only had median doses of CBD and THC of 45 and 10 mg/day
Citation: Gupta A, Erridge S, Graf V, Kelada M, Bapir L, Jesuraj N, Warner-Levy J, Clarke E, McLachlan K, Coomber R, Rucker JJ, Platt MW, Sodergren MH. UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2024 Dec;18(12):829-838. doi: 10.1080/17474124.2024.2443574. Epub 2025 Jan 9. PMID: 39689344.
